<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2508737</article-id><article-id pub-id-type="pmc">2247298</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Allum</surname><given-names>W. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hallissey</surname><given-names>M. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>L. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hockey</surname><given-names>M. S.</given-names></name></contrib></contrib-group><aff>Department of Surgery, Leicester Royal Infirmary, UK.</aff><pub-date pub-type="ppub"><month>11</month><year>1989</year></pub-date><volume>60</volume><issue>5</issue><fpage>739</fpage><lpage>744</lpage><abstract><p>A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups. With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00121-0093.tif" xlink:title="scanned-page" xlink:role="739" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00121-0094.tif" xlink:title="scanned-page" xlink:role="740" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00121-0095.tif" xlink:title="scanned-page" xlink:role="741" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00121-0096.tif" xlink:title="scanned-page" xlink:role="742" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00121-0097.tif" xlink:title="scanned-page" xlink:role="743" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00121-0098.tif" xlink:title="scanned-page" xlink:role="744" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

